Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma, Refractory Neuroblastoma
Conditions
Brief summary
This phase I/II trial studies the side effects and best dose of iberdomide when given together with chemoimmunotherapy drugs and to see how well it works in treating patients with neuroblastoma that has come back after a period of improvement (relapsed), that does not respond to treatment (refractory), or that is growing, spreading, or getting worse (progressive) following prior chemoimmunotherapy. Iberdomide is a cereblon-modulating agent. It works by helping the immune system kill tumor cells. Chemoimmunotherapy is chemotherapy combined with immunotherapy. Chemotherapy drugs, such as cyclophosphamide and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with dinutuximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Granulocyte-macrophage colony-stimulating factors (GM-CSF), such as sargramostim, may increase the production of blood cells and may help the immune system recover from the side effects of chemotherapy. Giving iberdomide with chemoimmunotherapy may be safe, tolerable, and/or effective in treating patients with relapsed, refractory, or progressive neuroblastoma following prior chemoimmunotherapy.
Detailed description
PRIMARY OBJECTIVES: I. To identify a recommended phase 2 dose (RP2D) of iberdomide administered in combination with dinutuximab, cyclophosphamide, topotecan, and GM-CSF in patients with relapsed, refractory, or progressive neuroblastoma previously treated with chemoimmunotherapy. (Phase 1 dose escalation) II. To evaluate whether the addition of iberdomide to dinutuximab, cyclophosphamide, topotecan, and GM-CSF is associated with an improved response rate compared to dinutuximab, cyclophosphamide, topotecan, and GM CSF in patients with refractory, relapsed, or progressive neuroblastoma previously treated with chemoimmunotherapy. (Phase 2 efficacy) SECONDARY OBJECTIVES: I. To evaluate the preliminary response rate of the addition of iberdomide to dinutuximab, cyclophosphamide, topotecan, and GM-CSF in patients with refractory, relapsed, or progressive neuroblastoma previously treated with chemoimmunotherapy. (Phase 1 dose escalation) II. To compare progression-free survival (PFS), overall survival (OS), confirmed response rate, and duration of response (DOR) between patients receiving dinutuximab, cyclophosphamide, topotecan, and GM-CSF with and without the addition of iberdomide. III. To describe the toxicity profile of the combination of dinutuximab, cyclophosphamide, topotecan, and GM-CSF with and without iberdomide. EXPLORATORY OBJECTIVES: I. To characterize the pharmacokinetics and pharmacodynamics of iberdomide in combination with dinutuximab, cyclophosphamide, topotecan, and GM-CSF. II. To characterize the circulating immune profile of patients treated with and without the addition of iberdomide to the dinutuximab, cyclophosphamide, topotecan, and GM-CSF backbone and explore associations with response to therapy. III. To evaluate associations between GD2 levels in tumor cells from patient bone marrow samples and response to therapy. IV. To collect and bank peripheral blood and tumor tissue (archival and fresh tissue from primary tumor resection or relapse, if available) for future biomarker studies. OUTLINE: This is a phase I, dose-escalation study of iberdomide in combination with cyclophosphamide (CPM), topotecan (Topo), dinutuximab (DIN) and sargramostim (GM-CSF) followed by a phase II study. Patients are assigned to 1 of 2 phases. PHASE 1: Patients receive iberdomide orally (PO), via nasogastric (NG)-tube, or via gastric (G)-tube once daily (QD) on days 1-14 or 1-21, cyclophosphamide intravenously (IV) over 15-30 minutes on days 1-5, topotecan IV over 30 minutes on days 1-5, dinutuximab IV over 10 hours on days 2-5, and sargramostim subcutaneously (SC) or IV over 2 hours starting on day 6 or 7 and continuing for a minimum of 7 doses until absolute neutrophil count (ANC) is ≥ 1500/μL after the expected nadir or until day 21 of each cycle. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. PHASE 2: Patients are randomized to 1 of 2 arms. ARM A: Patients receive cyclophosphamide IV over 15-30 minutes on days 1-5, topotecan IV over 30 minutes on days 1-5, dinutuximab IV over 10 hours on days 2-5, and sargramostim SC or IV over 2 hours starting on day 6 or 7 and continuing for a minimum of 7 doses until ANC is ≥ 1500/μL after the expected nadir or until day 21 of each cycle. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. ARM B: Patients receive iberdomide PO, via NG-tube, or via G-tube QD on days 1-14 or 1-21, as determined in phase 1, cyclophosphamide IV over 15-30 minutes on days 1-5, topotecan IV over 30 minutes on days 1-5, dinutuximab IV over 10 hours on days 2-5, and sargramostim SC or IV over 2 hours starting on day 6 or 7 and continuing for a minimum of 7 doses until ANC is ≥ 1500/μL after the expected nadir or until day 21 of each cycle. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Additionally, all patients undergo echocardiography (ECHO) or multigated acquisition scan (MUGA), bone marrow aspiration and biopsy, computed tomography (CT) or magnetic resonance imaging (MRI), and iobenguane I-123 (123I-MIBG) scans or fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) throughout the study. All patients also undergo blood sample collection on study. After completion of study treatment, patients are followed up at 30 days, 3, 6, and 12 months, every 6 months for years 2-3, and then yearly for years 4-5.
Interventions
PROCEDUREBone Marrow Aspiration
Undergo bone marrow aspiration
PROCEDUREBone Marrow Biopsy
Undergo bone marrow biopsy
PROCEDUREComputed Tomography
Undergo CT
DRUGCyclophosphamide
Given IV
BIOLOGICALDinutuximab
Given IV
PROCEDUREEchocardiography Test
Undergo ECHO
PROCEDUREFDG-Positron Emission Tomography
Undergo FDG-PET
DRUGIberdomide
Given PO, NG-tube, or G-tube
PROCEDUREMagnetic Resonance Imaging
Undergo MRI
PROCEDUREMultigated Acquisition Scan
Undergo MUGA
RADIATIONNuclear Radiology Imaging Procedure
Undergo 123I-MIBG scans
BIOLOGICALSargramostim
Given SC or IV
DRUGTopotecan
Given IV
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Phase 1: Dose escalation and determination of RP2D. Randomized Phase 2: The RP2D of iberdomide established in Phase 1 will be used as the treatment dose in Phase 2.
Eligibility
Sex/Gender
ALL
Age
1 Years to 30 Years
Healthy volunteers
No
Inclusion criteria
* Patients must be ≥ 1 year of age and ≤ 30 years of age at the time of study enrollment * Patients must have had histologic verification of neuroblastoma or ganglioneuroblastoma or demonstration of neuroblastoma cells in the bone marrow with elevated urinary catecholamines (i.e. \> 2 x upper limit of normal \[ULN\]), at the time of initial diagnosis * Progressive/relapsed or refractory (defined as persistent disease with overall response no better than minor response \[MR\] to prior therapy per revised International Neuroblastoma Response Criteria \[INRC\]) neuroblastoma based on the revised INRC * Patients must meet ONE of the following criteria: * Primary refractory disease * Primary refractory disease following chemoimmunotherapy as part of induction therapy (e.g., ANBL17P1, ANBL2131 Arm B). Patients with primary refractory disease must have received at least 4 cycles of frontline high-risk induction chemoimmunotherapy * Primary refractory disease following aggressive multi-drug induction chemotherapy on or according to a high-risk NB protocol (e.g., A3973, ANBL0532, ANBL09P1, ANBL12P1, ANBL1531, or ANBL2131 Arm A) with persistent disease at the conclusion of at least 4 cycles of chemoimmunotherapy used as extended induction or pre-consolidation intensification of therapy for primary refractory disease (e.g., ANBL2131 Arm A with extended induction, ANBL1221, or ANBL1821) * NOTE: Patients who experienced disease progression either during or within 30 days of completion (last day of anti-GD2 antibody) of chemoimmunotherapy during induction or extended induction are not eligible for the study * Relapsed/progressive disease * First episode of recurrence following chemoimmunotherapy as part of induction therapy (e.g., ANBL17P1, ANBL2131 Arm B) or extended induction (e.g., ANBL2131 Arm A) * NOTE: Patients who experienced disease progression either during or within 30 days of completion (last day of anti-GD2 antibody) of chemoimmunotherapy during induction or extended induction are not eligible for the study * First episode of recurrent/progressive disease detected during or following chemoimmunotherapy used as part of post-consolidation therapy (e.g., ANBL19P1) * Second episode of recurrent/progressive disease detected during or following chemoimmunotherapy used as first-line salvage therapy for recurrent or progressive disease (e.g., ANBL1221, ANBL1821) * Evaluable or measurable disease per the revised INRC * Measurable soft tissue disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 that is metaiodobenzylguanidine (MIBG) avid or demonstrates increased FDG uptake on PET scan * Evaluable disease is defined as either: * MIBG-avid lesions only (detected on MIBG scan with positive uptake at minimum of one site that do not meet criteria for measurable disease. This site(s) must represent disease recurrence after completion of therapy, progressive disease on therapy, or refractory disease during induction). OR * New bone site that is avid for FDG-PET (MIBG non-avid tumors) AND has CT/MRI findings consistent with tumor OR has been confirmed by biopsy * Patients with resistant/refractory soft tissue disease that is not MIBG avid or does not demonstrate increased FDG uptake on PET scan must undergo biopsy to document the presence of viable neuroblastoma to be considered a site of disease. Biopsy is not required for patients who have a new site of soft tissue disease or radiographic evidence of disease progression regardless of whether progression occurs while receiving therapy or after completion of therapy * NOTE: Patients with bone marrow only disease are not eligible. Patients with only elevated catecholamines (i.e. \> 2 x ULN) are also not eligible for this study * Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients \> 16 years of age and Lansky for patients ≤ 16 years of age * For the purposes of this study, "chemoimmunotherapy" is defined as a regimen utilizing any anti-GD2 antibody in combination with cytotoxic chemotherapy, with doses of chemotherapy similar to those used in ANBL1221, ANBL1821, ANBL17P1, ANBL2131, and ANBL19P1 * Patient must have received one and NO MORE THAN one prior chemoimmunotherapy-containing regimen * NOTE: Patients who received ANBL2131 Arm B therapy or a similar regimen including anti-GD2 antibody in combination with chemotherapy and then received an extended induction with chemoimmunotherapy (regardless of whether the chemoimmunotherapy was administered for relapse, progression, or poor end of induction response) will be considered to have received two regimens of chemoimmunotherapy. These patients are not eligible for this trial * Patient cannot have received more than two prior lines of therapy, including frontline therapy * Standard high-risk induction with or without extended induction followed by consolidation and post-consolidation immunotherapy with or without eflornithine (DFMO) continuation therapy will be considered one line of therapy * ANBL2131 Arm B induction without extended induction followed by consolidation and post-consolidation immunotherapy with or without DFMO continuation therapy will be considered one line of therapy * NOTE: Induction on ANBL2131 Arm B and extended induction are considered two separate regimens for the purposes of counting the number of chemoimmunotherapy regimens. In addition, patients who received ANBL2131 Arm B therapy or a similar regimen including anti-GD2 antibody in combination with chemotherapy who received another line of relapse therapy following Arm B or similar treatment are also not eligible * In the relapse setting, one line of therapy will be considered at least one delivered cycle of chemoimmunotherapy (with no limit on the number of consecutive cycles of chemoimmunotherapy) * NOTE: A change in the chemotherapy regimen or anti-GD2 antibody will be considered an additional line of chemoimmunotherapy and these patients will not be eligible for the trial * In the refractory setting where chemoimmunotherapy was used as extended induction or pre-consolidation intensification of therapy for primary refractory disease, one line of therapy will be considered at least 4 delivered cycles of chemoimmunotherapy (with no limit on the number of consecutive cycles of chemoimmunotherapy) * NOTE: A change in the chemotherapy regimen or anti-GD2 antibody will be considered an additional line of chemoimmunotherapy and these patients will not be eligible for the trial * Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study * Myelosuppressive chemotherapy: Must not have received within 14 days (2 weeks) of entry onto this study * Biologic (anti-neoplastic agent): Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or ANC counts): ≥ 7 days after the last dose of agent. See Developmental Therapeutics Committee (DVL) homepage for commercial and Phase 1 investigational agent classifications * Antibodies: ≥ 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade ≤ 1 * Radiation therapy (RT): * ≥ 7 days must have elapsed from small port radiation; ≥ 12 weeks must have elapsed from large field radiation therapy (i.e., total body irradiation, craniospinal, whole abdominal, total lung, \> 50% marrow space); ≥ 6 weeks from other substantial bone marrow radiation * Lesions that have been previously radiated cannot be used as target lesions unless there is radiographic evidence of progression at the site following radiation or a biopsy done following radiation shows viable neuroblastoma. Palliative radiation while on study is not permitted * Stem cell transplant (SCT): Patients are eligible ≥ 6 weeks after autologous stem cell transplants or stem cell infusions (including stem cell infusions given as supportive care following iobenguane I-131 \[131I-MIBG\] therapy) as long as hematologic and other eligibility criteria have been met * 131I-MIBG therapy: Patients who previously received 131I-MIBG therapy for relapsed/refractory disease or poor end of induction response are not eligible * Prior receipt of 131I-MIBG therapy as part of planned frontline Induction therapy (e.g., ANBL09P1, ANBL1531) is allowed. Patients are eligible ≥ 6 weeks after therapeutic 131I-MIBG provided that all other eligibility criteria are met * Growth factor: Patients must not have received long-acting myeloid growth factors (e.g. pegfilgrastim) within 14 days of entry on this study. Seven days must have elapsed since administration of a short-acting myeloid growth factor or platelet growth factor/stimulating agents (e.g., romiplostim, eltrombopag) * Intravenous immunoglobulin (IVIG): Patients must not have received IVIG within 14 days of study entry * Known HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial * Peripheral absolute neutrophil count (ANC) ≥ 1000/uL (performed within 7 days prior to enrollment) * Patients known to have bone marrow involvement with neuroblastoma are eligible provided that the minimum ANC and transfusion independent platelet count criteria are met * Platelet count ≥ 100,000/uL (transfusion independent) (performed within 7 days prior to enrollment) * Patients known to have bone marrow involvement with neuroblastoma are eligible provided that the minimum ANC and transfusion independent platelet count criteria are met * A serum creatinine based on age/sex as follows: (performed within 7 days prior to enrollment) * Age: 1 to \< 2 years; Maximum serum creatinine (mg/dL): 0.6 (male) 0.6 (female) * Age: 2 to \< 6 years; Maximum serum creatinine (mg/dL): 0.8 (male) 0.8 (female) * Age: 6 to \< 10 years; Maximum serum creatinine (mg/dL): 1 (male) 1 (female) * Age: 10 to \< 13 years; Maximum serum creatinine (mg/dL): 1.2 (male) 1.2 (female) * Age: 13 to \< 16 years; Maximum serum creatinine (mg/dL): 1.5 (male) 1.4 (female) * Age: ≥ 16 years; Maximum serum creatinine (mg/dL): 1.7 (male) 1.4 (female) OR - a 24-hour urine creatinine clearance ≥ 60 mL/min/1.73 m\^2 OR - a glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m\^2. If used for eligibility, GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard) * Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age or ≤ 3.0 mg/dL for patients with documented Gilbert's syndrome (performed within 7 days prior to enrollment) * Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase \[ALT\]) ≤ 135 U/L (performed within 7 days prior to enrollment) * Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L * Shortening fraction of ≥ 27% by echocardiogram (ECHO), OR ejection fraction of ≥ 50% by ECHO or grated radionuclide study (obtained within 21 days prior to enrollment and start of protocol therapy) * No evidence of dyspnea at rest, no exercise intolerance, no chronic oxygen requirement, and room air pulse oximetry \> 94% if there is a clinical indication for pulse oximetry. Normal pulmonary function tests in patients who are capable of cooperating with testing (including diffusion capacity of the lung for carbon monoxide \[DLCO\]) are required if there is a clinical indication for determination. For patients who do not have respiratory symptoms, full pulmonary function testing (PFTs) are NOT required (obtained within 21 days prior to enrollment and start of protocol therapy) * Patients with a history of central nervous system (CNS) metastatic disease must have no clinical or radiological evidence of active CNS disease at the time of study enrollment. Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled * CNS toxicity ≤ grade 2
Exclusion criteria
* Patients who received allogeneic stem cell therapy will be excluded * Patients must have been off pharmacologic doses of systemic steroids for at least 7 days prior to enrollment. Patients who require or are likely to require pharmacologic doses of systemic corticosteroids while receiving treatment on this study are ineligible. The only exception is for patients known to require 2 mg/kg or less of hydrocortisone (or an equivalent dose of an alternative corticosteroid) as premedication for blood product administration in order to avoid allergic transfusion reactions. The use of conventional doses of inhaled steroids for the treatment of asthma is permitted, as is the use of physiologic doses of steroids for patients with known adrenal insufficiency. Patients on any other immunosuppressive medications (e.g. cyclosporine, tacrolimus) are not eligible * Patients with untreated CNS disease will be excluded. If the CNS disease has been adequately treated (e.g., surgical resection and radiation; or radiation alone) and there is no evidence of progression in the CNS, then the patient will be eligible * Patients with a history of having to permanently discontinue anti-GD2 therapy or sargarmostim (GM-CSF) due to drug-related toxicity will be excluded * Patients with a history of grade 4 allergic reactions or other drug-related toxicities that required permanent discontinuation of dinutuximab, dinutuximab-beta, or sargarmostim (GM-CSF) will be excluded * Patients with myelodysplastic syndrome or with any other malignancy other than neuroblastoma will be excluded * Patients with prior exposure to iberdomide will be excluded * Patients with a history of serious allergic reaction to another immunomodulatory agent (e.g., thalidomide, lenalidomide, or pomalidomide) will be excluded * Patients who are unable to tolerate oral/nasogastric/gastrostomy medications will not be eligible for this trial. Additionally, patients with significant malabsorption such as chronic gastrointestinal diseases (e.g., inflammatory bowel disease) or significant bowel resection that would preclude adequate oral medication absorption will be excluded * Patients must not have received enzyme-inducing anticonvulsants including but not limited to phenytoin, phenobarbital, or carbamazepine for at least 7 days prior to study enrollment. Patients receiving non-enzyme inducing anticonvulsants such as gabapentin, valproic acid, or levetiracetam will be eligible * Patients who have received drugs that are strong inducers or inhibitors of CYP3A4 within 14 days prior to study enrollment are not eligible * Patients with history of prior unprovoked thrombosis/thromboembolic events are not eligible. Patients with a history of provoked thrombosis/thromboembolic events (e.g., related to central lines) are eligible if they no longer require anti-coagulation or have been on a stable dose of anticoagulation therapy for at least 6 weeks before the first dose of study treatment and have no complications from the thrombosis/thromboembolic event or the anticoagulation regimen * Patients who have an uncontrolled infection are not eligible * Patients with peripheral neuropathy ≥ grade 2 are excluded * Patients with a significant intercurrent illness (any ongoing serious medical problem unrelated to cancer or its treatment) that is not covered by the detailed
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of therapy-associated dose limiting toxicities (Phase 1) | During cycle 1 (Cycle length = 28 days) | Graded using Common Terminology Criteria for Adverse Events version 5.0. |
| Recommended phase 2 dose (Phase 1) | Up to the completion of phase 1 | Will be assessed by determining the recommended phase 2 dose of iberdomide administered in combination with dinutuximab, cyclophosphamide, topotecan, and granulocyte-macrophage colony-stimulating factor (GM-CSF) using the rolling six design. |
| Proportion of eligible patients who are responders (Phase 2) | Post-randomization up through the end of cycle 12 (Cycle length = 28 days) | Responders are defined as patients who achieve a minor response (MR) or better, per the revised International Neuroblastoma Response Criteria (INRC), as their best overall response at any time post-randomization up through the end of cycle 12. Will be evaluated by Boschloo's test to compare the response rates in the two arms, and the futility monitoring rules. The response rate by the end of 12 cycles as determined by central review will be calculated in each arm, including placement of a 95% confidence interval (CI). If the response rate on Arm B is significantly better, then it will be considered a therapeutic regimen worthy of further testing in patients with high-risk neuroblastoma. In addition, the rate of complete response + partial response by the end of 12 cycles as determined by central review will be calculated in each arm, including placement of a 95% CI, as well as response within each of the INRC components. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response rate (Phase 1) | Up to 12 cycles (Cycle length = 28 days) | The response rate by the end of 12 cycles as determined by the institution will be calculated in the whole cohort, including placement of a 95% CI. |
| Progression-free survival (Phase 2) | From the time of randomization to the occurrence of relapse, progressive disease, or death, assessed up to 5 years | Will be assessed for Phase 2 patients receiving dinutuximab, cyclophosphamide, and topotecan with and without the addition of iberdomide. Kaplan-Meier curves will be generated by arm and compared using log-rank tests. |
| Overall survival (Phase 2) | From the time of randomization to death, assessed up to 5 years | Will be assessed for Phase 2 patients receiving dinutuximab, cyclophosphamide, and topotecan with and without the addition of iberdomide. Kaplan-Meier curves will be generated by arm and compared using log-rank tests. |
| Duration of response | From randomization to disease progression or death in eligible patients, except those placed off study due to lack of insurance coverage, who achieve a MR or better, assessed up to 5 years | The confirmed response rate and duration of response, along with summary statistics, will be calculated in each arm. |
| Incidence of grade ≥ 3 toxicities (Phase 2 Arm B) | Up to 5 years post-treatment | Toxicities (grade ≥ 3) experienced on Arm B will be descriptively summarized. |
Contacts
PRINCIPAL_INVESTIGATORKieuhoa T Vo
Children's Oncology Group
Outcome results
None listed